XELOXvs.FOLFOX in metastatic colorectal cancer: An updated meta-analysis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
XELOXvs.FOLFOX in metastatic colorectal cancer: An updated meta-analysis
Authors
Keywords
-
Journal
CANCER INVESTIGATION
Volume 34, Issue 2, Pages 94-104
Publisher
Informa UK Limited
Online
2016-02-11
DOI
10.3109/07357907.2015.1104689
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): Impact of age on disease-free survival (DFS).
- (2017) D. G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
- (2012) R-D Hofheinz et al. BRITISH JOURNAL OF CANCER
- Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01
- (2012) Kelley M. Kidwell et al. CANCER
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
- (2010) Michel Ducreux et al. INTERNATIONAL JOURNAL OF CANCER
- Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
- (2009) T Conroy et al. BRITISH JOURNAL OF CANCER
- Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis
- (2009) G. Zhao et al. Colorectal Disease
- Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner â meta-analysis of six randomized trials
- (2009) Y. Cao et al. Colorectal Disease
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
- (2008) M. L. Rothenberg et al. ANNALS OF ONCOLOGY
- Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer
- (2008) Hendrik-Tobias Arkenau et al. Clinical Colorectal Cancer
- Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study
- (2008) Javier Sastre et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
- (2008) Hendrik-Tobias Arkenau et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
- (2008) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
- (2008) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More